These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 28230637

  • 1. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
    Paoletti E.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
    [Abstract] [Full Text] [Related]

  • 2. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E, Cannella G.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [Abstract] [Full Text] [Related]

  • 3. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract] [Full Text] [Related]

  • 4. mTOR Inhibition and Kidney Diseases.
    Ma MKM, Yung S, Chan TM.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [Abstract] [Full Text] [Related]

  • 5. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
    Berney T, Andres A, Toso C, Majno P, Squifflet JP.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A, Más-Serrano P, Perez Contreras J, Jiménez L, Rodriguez D, Olivares J.
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A, Osorio-Jaramillo E, Aliabadi-Zuckermann AZ.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H.
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
    Malvezzi P, Jouve T, Rostaing L.
    Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
    Badve SV, Pascoe EM, Burke M, Clayton PA, Campbell SB, Hawley CM, Lim WH, McDonald SP, Wong G, Johnson DW.
    Clin J Am Soc Nephrol; 2016 Oct 07; 11(10):1845-1855. PubMed ID: 27445164
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan 07; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.